Healthcare / Drug Manufacturers - Specialty & GenericBSE
$49.46
-0.15 (-0.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-171.6M · quality 75.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
41.2%
↑Gross Margin
9.6%
↓Debt/Equity
-2.57
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+53.9%
FCF CAGR
—
FCF margin
-35.9%
FCF / Net income
2.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.13B · net income $-175.7M · FCF $-406.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.13B | $1.13B | $1.09B | $396.4M | $309.9M |
| Net Income | $-175.7M | $-175.7M | $-103.0M | $-34.8M | $-115.7M |
| EBITDA | $-150.8M | $-150.8M | $-87.8M | $-96.3M | $-78.5M |
| EPS | — | — | -2.86 | -1.09 | -8.15 |
| Gross Margin | 9.6% | 9.6% | 11.7% | -3.3% | 1.3% |
| Operating Margin | -15.7% | -15.7% | -12.5% | -31.1% | -29.5% |
| Net Margin | -15.6% | -15.6% | -9.4% | -8.8% | -37.3% |
| Balance Sheet | |||||
| Debt/Equity | -2.57 | -2.57 | -2.49 | -2.84 | -1.47 |
| Cash Flow | |||||
| Free Cash Flow | $-406.1M | $-406.1M | $-85.6M | $-171.6M | $-112.8M |
| Returns | |||||
| ROE | 41.2% | 41.2% | 41.2% | 17.3% | 25.0% |
| Growth & Yield | |||||
| Revenue Growth | 3.4% | 3.4% | 175.7% | 27.9% | — |
| EPS Growth | — | — | -162.4% | 86.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-43.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.86 → n/d
Residual
-43.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.